Msonthi Levine, MD
Internal Medicine · Beaumont, TXNPI 1962430413
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 560 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 58 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,379 and has fallen 69.6% since, to $724 in 2025. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 560 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- AbbVie$1K
- Novo Nordisk$711
- Pfizer$637
- Johnson & Johnson$555
- plus $4K from 52 others
What the payments were for
- Food & beverage$9,70099%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$126
- SYMBICORT$126
- BYDUREON$126
- BEVESPI AEROSPHERE$126
How this compares
$9,766 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 439 | $322,497 |
| FarxigaDapagliflozin Propanediol | 233 | $207,706 |
| OzempicSemaglutide | 104 | $167,342 |
| RybelsusSemaglutide | 87 | $146,078 |
| JardianceEmpagliflozin | 136 | $130,824 |
| MounjaroTirzepatide | 93 | $124,705 |
| TrulicityDulaglutide | 80 | $121,610 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 135 | $115,697 |
| LinzessLinaclotide | 77 | $75,392 |
| RexultiBrexpiprazole | 31 | $51,448 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $49,757 |
| MyrbetriqMirabegron | 77 | $39,501 |
| EntrestoSacubitril/Valsartan | 35 | $37,404 |
| AustedoDeutetrabenazine | 13 | $33,558 |
| Bydureon BciseExenatide Microspheres | 30 | $31,632 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $711 | $338,174205 claims |
| PfizerEliquis, Premarin | $637 | $330,555465 claims |
| Lilly USA, LLCMounjaro, Trulicity | $541 | $246,315173 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,211 | $224,788256 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,122 | $142,870185 claims |
| Boehringer IngelheimJardiance | $283 | $130,824136 claims |
| AbbVieLinzess, Qulipta | $1,032 | $104,11091 claims |
| MerckJanuvia, Janumet, Belsomra | $254 | $56,17978 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $98 | $51,44831 claims |
| NovartisEntresto | $367 | $37,40435 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $89 | $33,55813 claims |
| Johnson & JohnsonXarelto | $555 | $18,41915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Beaumont
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.